This AI trading robot "Day Trader: Medium Volatility Stocks for Active Trading (TA&FA)", was one of the best in our robot factory, generating a 7.12% gain for OCGN over the course of the previous week.
As per the technical analysis, the Stochastic Oscillator for OCGN moved out of oversold territory on April 13, 2023, which could indicate a shift from a downward trend to an upward trend. This may be considered a bullish signal for traders who may want to buy the stock or buy call options.
Tickeron's A.I.dvisor analyzed 79 instances where the Stochastic Oscillator left the oversold zone and found that in 73 of those cases, the stock price moved higher in the following days. This gives a probability of over 90% for a continued upward trend in the case of OCGN.
However, traders should also consider other factors such as market conditions, company news, and earnings reports before making any investment decisions. It's important to note that short-term gains may not necessarily be sustainable in the long run. Therefore, it's crucial to conduct thorough research and analysis before making any investment decisions.
Day Trader: Medium Volatility Stocks for Active Trading (TA&FA)
The 10-day RSI Oscillator for OCGN moved out of overbought territory on June 17, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 instances where the indicator moved out of the overbought zone. In of the 19 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OCGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
OCGN broke above its upper Bollinger Band on July 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Momentum Indicator moved above the 0 level on July 08, 2025. You may want to consider a long position or call options on OCGN as a result. In of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for OCGN just turned positive on July 10, 2025. Looking at past instances where OCGN's MACD turned positive, the stock continued to rise in of 56 cases over the following month. The odds of a continued upward trend are .
The 50-day moving average for OCGN moved above the 200-day moving average on June 24, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where OCGN advanced for three days, in of 225 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 87 cases where OCGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. OCGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.921) is normal, around the industry mean (17.292). P/E Ratio (0.000) is within average values for comparable stocks, (58.926). OCGN's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.456). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (70.423) is also within normal values, averaging (272.270).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OCGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company, which engages in the development and commercialization of therapies for eye diseases
Industry Biotechnology